Traditional Chinese Medicine Ion Introduction Therapy Reduces the Incidence of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study

Int J Gen Med. 2025 Jan 6:18:21-32. doi: 10.2147/IJGM.S498350. eCollection 2025.

Abstract

Objective: To evaluate the effectiveness and safety of traditional Chinese medicine (TCM) ion introduction therapy in the treatment of patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF).

Methods: This study adopts a prospective cohort study design, with 60 AE-IPF patients as the research subjects. Divided into an exposed group and a non exposed group, with 30 cases in each group, based on the frequency of TCM ion introduction treatment as the exposure factor. Follow-up for 1 year to observe the acute exacerbation of the patient. The main indicator is the annual incidence of acute exacerbation, and the secondary indicators are hospitalization time, readmission rate, time to first acute exacerbation, mortality rate, all-cause mortality rate, inflammatory indicators, quality of life, etc.

Results: 51 patients completed a one-year clinical observation, including 27 in the exposed group and 24 in the non exposed group. Compared to the non exposed group, significant differences were observed in the annual incidence of acute exacerbation [incidence rate ratios (IRR) = 0.556, 95% CI: 0.315, 0.980; P = 0.035] and hospitalization time (P = 0.040), readmission rate (IRR = 0.533, 95% CI: 0.288, 0.988; P = 0.037), time to first acute exacerbation (P = 0.045), and quality of life (P < 0.05). However, there was no statistically significant difference in mortality rate and all-cause mortality rate between the two groups (P > 0.05).

Conclusion: Compared to the non exposed group, TCM ion introduction can reduce the annual incidence of acute exacerbation of IPF patients. Hospitalization time, readmission rate, time to first acute exacerbation, quality of life improved, but mortality rate and all-cause mortality rate did not improve.

Keywords: TCM; acute exacerbation; idiopathic pulmonary fibrosis; incidence; ion introduction.

Publication types

  • Case Reports
  • Clinical Trial

Grants and funding

The study was supported by the National Key Research and development Program (No. 2023YFC3502601), Natural Science Foundation of Henan Youth Fund (No. 212300410056), National Natural Science Foundation of China (No.81830116), Henan Province Scientific Research Project - Double First-Class Traditional Chinese medicine (HSRP-DFCTCM-2023-3-16, DFCTCM-2023-4-05), Special Project of Traditional Chinese Medicine Research of Henan Province (20-21ZY2186), Special Project of Traditional Chinese Medicine Research of Henan Province (2023ZY2055), the Henan Province Medical Science and Technology Program (No.LHGJ20220586) and Henan Province Second Batch of Top-notch Chinese Medicine Talent Projects (2021 No.15).